Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Melanoma 7Carcinoma, Non-Small-Cell Lung 6Neoplasms 5Multiple Myeloma 3Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Hematologic Neoplasms 2Erdheim-Chester Disease 2Xanthogranuloma, Juvenile 1Thyroid Neoplasms 1Skin Neoplasms 1Sarcoma 1Pancreatic Adenocarcinoma 1Neoplasms, Unknown Primary 1Microsatellite Unstable Colorectal Cancer 1Lymphoproliferative Disorders 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Laryngeal Neoplasms 1Inflammatory Breast Neoplasms 1Histiocytosis, Sinus 1Histiocytosis, Langerhans-Cell 1Histiocytic Sarcoma 1Histiocytic Disorders, Malignant 1

Interventions

Magnetic Resonance Spectroscopy 5trametinib 3Specimen Handling 3dabrafenib 2cabozantinib 2X-Rays 2Iodine-131 2Interviews as Topic 2tremelimumab 1spartalizumab 1pembrolizumab 1omipalisib 1lenvatinib 1gallium Ga 68 dotatate 1durvalumab 1cobimetinib 1Vemurafenib 1Thyrotropin Alfa 1Sodium Iodide 1Phantoms, Imaging 1Nivolumab 1Ipilimumab 1Iodine-124 1High-Energy Shock Waves 1Glycoprotein Hormones, alpha Subunit 1Counseling 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Follicular × cobimetinib × 1 year × Clear all
NCT06440850 2026-02-02

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

City of Hope Medical Center

Phase 2 Recruiting
21 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡